Literature DB >> 34213403

A review of the experience of childhood hepatitis A vaccination in Saudi Arabia and Turkey: implications for hepatitis A control and prevention in the Middle East and North African region.

Selim Badur1, Serdar Öztürk1, Alev Ozakay1, Mansour Khalaf2, Debasish Saha3, Pierre Van Damme4.   

Abstract

In most countries of the Middle East and Northern African (MENA) region, a high hepatitis A virus (HAV) endemicity has been documented. Few others, such as Saudi Arabia and Turkey, are transitioning from high to intermediate endemicity. There is a paucity of recently published HAV disease burden that could be useful to inform or strengthen relevant national hepatitis A vaccination policy and other prevention strategies in the region. This review summarizes information on HAV epidemiology before and after the implementation of a childhood hepatitis A vaccination program in Saudi Arabia and Turkey. In both countries, a clear shift in the age of first HAV exposure has been documented, with more homogeneous trends across regions in Saudi Arabia compared to Turkey. Utilizing the experience of Saudi Arabia and Turkey with hepatitis A vaccination, countries in the region are encouraged to foster discussions on potential vaccination strategies suitable for their own setting.

Entities:  

Keywords:  Hepatitis A; Middle East; Saudi Arabia; Turkey; endemicity; seroprevalence; vaccination

Mesh:

Substances:

Year:  2021        PMID: 34213403      PMCID: PMC8437515          DOI: 10.1080/21645515.2021.1920871

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  64 in total

1.  The seroprevalence of anti-HAV among 0-16-year-olds referred to pediatric outpatients clinics of a hospital.

Authors:  B Ersoy; A Aydoğan; A Dinçoğuz; M Sinan Meral; T Turul
Journal:  J Trop Pediatr       Date:  1998-02       Impact factor: 1.165

2.  Hepatitis A virus among natives and expatriates in Saudia Arabia.

Authors:  S J Ashraf; S C Arya; C M Parande; E Kristensen
Journal:  J Med Virol       Date:  1986-06       Impact factor: 2.327

3.  Seroprevalence of hepatitis A virus markers in Eastern Saudi Arabia.

Authors:  S E Fathalla; A A Al-Jama; I H Al-Sheikh; S I Islam
Journal:  Saudi Med J       Date:  2000-10       Impact factor: 1.484

Review 4.  Globalization and the Changing Epidemiology of Hepatitis A Virus.

Authors:  Kathryn H Jacobsen
Journal:  Cold Spring Harb Perspect Med       Date:  2018-10-01       Impact factor: 6.915

5.  Seroprevalence survey of varicella, measles, rubella, and hepatitis A and B viruses in a multinational healthcare workforce in Saudi Arabia.

Authors:  M A Almuneef; Z A Memish; H H Balkhy; B Otaibi; M Helmi
Journal:  Infect Control Hosp Epidemiol       Date:  2006-10-17       Impact factor: 3.254

6.  GIS based spatial pattern analysis: Children with Hepatitis A in Turkey.

Authors:  Ahmet Ozgur Dogru; Ruusa Magano David; Necla Ulugtekin; Cigdem Goksel; Dursun Zafer Seker; Seval Sözen
Journal:  Environ Res       Date:  2017-04-06       Impact factor: 6.498

7.  Epidemiological shift of hepatitis A in central Adana, Turkey.

Authors:  Emre Alhan; Banu Kozanoğlu; Gökhan Tümgör; Ümit Çelik; Akgün Yaman; Nafiz Bozdemir
Journal:  Turk J Gastroenterol       Date:  2014-12       Impact factor: 1.852

8.  Seroprevalence of hepatitis a and associated factors among 1-15 year old children in Eastern Turkey.

Authors:  Serap Karaman; Kamuran Karaman; Baran Serdar Kızılyıldız; Nesrin Ceylan; Sultan Kaba; Mehmet Parlak; Burhan Beger; Abdullah Ceylan
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 9.  Profiling infectious diseases in Turkey after the influx of 3.5 million Syrian refugees.

Authors:  Ö Ergönül; N Tülek; I Kayı; H Irmak; O Erdem; M Dara
Journal:  Clin Microbiol Infect       Date:  2019-07-05       Impact factor: 8.067

10.  Hepatitis A seroprevalence in patients with chronic viral hepatitis in Konya, Turkey.

Authors:  Hale T Özden
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-03       Impact factor: 2.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.